200 research outputs found
Simple interventions for important problems and when doing nothing--or very little--is the best option. A simple lesson: Superga and the diabetic foot. A 5-year study.
No full textImprovements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study on venous segments.
No full text
Pycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55.
No full textInvestigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study.
No full textPycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55
No full textAIM: This 12-week, product-evaluation registry study aimed to compare the effects of supplementation with French Pine Bark Extract (Pycnogenol®) on cognitive function, attention, and mental performance in healthy professionals with increased oxidative stress in a professional context.
METHODS: Professionals were screened for increased oxidative stress: 60 subjects (range 35-55 years, no risk conditions, no addictions) voluntarily decided to be followed-up. Diet, alcohol and lifestyle patterns, including exercise, were controlled. Pycnogenol® (150 mg/day) was used in combination with a health plan to enhance mental performance and control oxidative stress.
RESULTS: A group of 30 professionals used Pycnogenol®, and 29 acted as comparable controls for a period of 12 weeks. The two registry groups were comparable. Cognitive function, attention, mental performance, sustained attention, memory, executive functions, mood and oxidative stress values were comparable at inclusion. At 12 weeks the improvement in Pycnogenol® subjects was more significant than in controls. Plasma-free radicals (oxidative stress) were significantly decreased (median -30.4%) at 12 weeks in Pycnogenol® subjects in comparison with a non-significant variation observed in controls (+0.9%; difference between groups). Considering the cognitive test battery (PASAT, pattern recognition memory, spatial recognition memory, spatial working memory), Pycnogenol® subjects showed a small but significant improvement with spatial recognition memory unchanged. Mood parameters (alertness, anxiety, contentedness) also improved in professionals using the supplement. In the evaluation of 12 professional daily tasks all items were improved with Pycnogenol® supplementation. The score relative to semi-professional minitasks was improved more in Pycnogenol® subjects. Tolerability and compliance were optimal with >94% of the doses of supplement correctly used.
CONCLUSION: Pycnogenol® supplementation for 12 weeks appears to improve cognitive function and oxidative stress in healthy professionals
Improvement in symptoms and cochlear flow with pycnogenol in patients with Meniere's disease and tinnitus
No full textAIM:
The aim of this supplement registry was to evaluate the efficacy of the Pycnogenol® in improving cochlear flow and symptoms in a 6-month follow-up for patients with Meniere's disease (MD), tinnitus and cochlear hypoperfusion.
METHODS:
Main signs/symptoms were considered: Spontaneous vertigo, positional vertigo, hearing loss, tinnitus, pressure in the ear, unsteady gait, associated clinical problems, alterations in daily life. All subjects were managed with the best available management (BM); one group used the supplement Pycnogenol (150 mg/day). Cochlear flow and tinnitus were also evaluated. Out of 120 patients incuded in the registry, 55 used Pycnogenol and 52 (controls) were managed only with BM.
RESULTS:
There was a more significant improvement in all registry items at 3 and 6 months in the Pycnogenol group (P<0.05). The number of lost working days was lower in the Pycnogenol group. At 3 months, 45.4% of subjects using Pycnogenol were completely asymptomatic in comparison with 23.07% of controls. At 6 months 87.3% of the Pycnogenol subjects were asymptomatic compared with 34.6% of controls. Cochlear flow velocity was significantly better (higher flow, higher diastolic component) in the Pycnogenol group (P<0.05). The subjective tinnitus scale decreased in both groups (P<0.05); the decrease was more significant in Pycnogenol subjects (P<0.05) at 3 and 6 months.
CONCLUSION:
Symptoms of Meniere's disease, flow at cochlear level and tinnitus improved in Pycnogenol subjects in comparison with best management
Improvement of common cold with Pycnogenol®: a Winter registry study
No full textAIM:
This registry study aimed to evaluate the use of Pycnogenol® (pine bark extract), an anti-inflammatory, anti-oxidant and anti-edema natural compound, on symptoms of common cold. Main targets were the evaluation in otherwise healthy subjects of signs/symptoms, the reduction in days of disease, and the prevention of complications.
METHODS:
All subjects used the "best management" for colds and one group added Pycnogenol® capsules (50 mg, bid/die) from day zero. The resulting registry groups were comparable. A total of 70 subjects used Pycnogenol® and 76 acted as controls.
RESULTS:
The number of days with a perceived cold affecting the patients was reduced in the supplement group (3.1;0.4 days) in comparison with controls (4.2;0.2). Lost working days were significantly decreased in the supplement group (0.55;0.3 versus 0.67;0.3 in controls). The need to use any other compound (on demand basis; OTC products) to manage symptoms and the occurrence of any clinically significant complications were significantly lower in the Pycnogenol® group. The most frequent complications were the extension of the cold to a period longer than 4 days, a tracheal extension and a bronchial involvement. Pycnogenol® was significantly effective in reducing the number of complications. The daily evolution of the "pillar cold signs" indicates a significantly faster resolution in the supplement group. With supplementation the decrease in symptom scores appears to be significantly more important. Pycnogenol® supplementation appears to make regression faster for all symptoms in comparison with controls.
CONCLUSION:
In this pilot registry, Pycnogenol® appears to decrease symptoms of cold and shorten its course also preventing some complication
Microcirculatory efficacy of topical treatment with aescin+essential phospholipids gel on trascutaneous PO2 in venous insufficiency
No full textMeriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study
No full textThe aim of this registry evaluation study was to compare, in symptomatic BPH patients, two management plans based on a currently validated standard treatment [defined as the best standard management (BSM)] including or not curcumin (administered as Meriva®) as a further complementary adjuvant element. Signs and symptoms were evaluated using the International Prostate Symptom Score (IPSS). SUBJECTS, METHODS: The study was carried out on a total of 61 subjects. 33 subjects (mean age 58.6;5.3) completed the survey with at least 24 weeks of treatment with Meriva® in association with the BSM. The BSM-alone control group consisted of 28 volunteers of similar age (58.4 years;3.4) and severity of the condition. The range of inclusion age was 55-65. No other clinical or metabolic problems were present. Meriva® was administered at the dosage of 2 tablets/day (2 x 500 mg of Meriva®/day, corresponding to 2 x 100 mg curcumin/day) with a compliance values > 95% as evaluated by the number of tablets used according to medical recommendation. No other drugs or food supplement were used during the study
- …
